AR106543A1 - Terapia de combinación de agente neutralizante de ntn1 con fármacos que inhiben el control epigenético - Google Patents

Terapia de combinación de agente neutralizante de ntn1 con fármacos que inhiben el control epigenético

Info

Publication number
AR106543A1
AR106543A1 ARP160103327A ARP160103327A AR106543A1 AR 106543 A1 AR106543 A1 AR 106543A1 AR P160103327 A ARP160103327 A AR P160103327A AR P160103327 A ARP160103327 A AR P160103327A AR 106543 A1 AR106543 A1 AR 106543A1
Authority
AR
Argentina
Prior art keywords
ntn1
neutralizing agent
composition
inhibitor
netrin
Prior art date
Application number
ARP160103327A
Other languages
English (en)
Original Assignee
Netris Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Netris Pharma filed Critical Netris Pharma
Publication of AR106543A1 publication Critical patent/AR106543A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/15—Depsipeptides; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Pain & Pain Management (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La composición farmacéutica o anticancerígena para el tratamiento de un cáncer que tiene una pérdida dependiente de la metilación de ADN, de la expresión de NTN1, UNC5H o DAPK1. Además se refiere a un método de tratamiento de dichos tipos de cáncer. La composición comprende un fármaco epigenético y un agente neutralizante de NTN1 o un vector capaz de expresar un agente neutralizante de NTN1 in vivo, en un portador o vehículo farmacéuticamente aceptable. El agente neutralizante de NTN1, tal como un anticuerpo que se une a netrina-1 o a un receptor de netrina-1, promueve la apoptosis inducida por receptores de netrina-1. El fármaco epigenético puede ser un inhibidor de ADN metiltransferasa o un inhibidor de HDAC. Reivindicación 1: Una composición farmacéutica que comprende un fármaco epigenético seleccionado de un inhibidor de la metilación de ADN y un inhibidor que tiene actividad inhibidora de histona, y un agente neutralizante de NTN1 o un vector capaz de expresar un agente neutralizante de NTN1 in vivo, en un portador o vehículo farmacéuticamente aceptable. Reivindicación 7: La composición de la reivindicación 6, donde el inhibidor de ADN metiltransferasa se selecciona del grupo que consiste en azacitidina; decitabina; zebularina; 5,6-dihidro-5-azacitidina; 5-fluoro-2’-desoxicitidina; NPEOC-DAC; CP-4200; y decitabina-p-desoxiguanosina (SGl-110), procainamida, procaína, hidralazina, (-)-epigalocatequin-3-galato (EGCG), N-ftalil-1-triptófano (RG108) y SGI-1027. Reivindicación 9: La composición de la reivindicación 8, donde el inhibidor de HDAC es un ácido hidroxámico o un péptido cíclico. Reivindicación 14: La composición para el uso de acuerdo con la reivindicación 11, 12 ó 13, que comprende el fármaco epigenético y el agente neutralizante de NTN1 o vector capaz de expresar un agente neutralizante de NTN1 in vivo, para una administración simultánea, separada o secuencial a un paciente.
ARP160103327A 2015-11-02 2016-11-01 Terapia de combinación de agente neutralizante de ntn1 con fármacos que inhiben el control epigenético AR106543A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP15306743 2015-11-02

Publications (1)

Publication Number Publication Date
AR106543A1 true AR106543A1 (es) 2018-01-24

Family

ID=54478684

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP160103327A AR106543A1 (es) 2015-11-02 2016-11-01 Terapia de combinación de agente neutralizante de ntn1 con fármacos que inhiben el control epigenético

Country Status (3)

Country Link
AR (1) AR106543A1 (es)
TW (1) TW201720459A (es)
WO (1) WO2017076864A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112574990A (zh) * 2020-12-11 2021-03-30 武汉大学 沉默人DAPK1基因表达的shRNA分子及其应用

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4444887A (en) 1979-12-10 1984-04-24 Sloan-Kettering Institute Process for making human antibody producing B-lymphocytes
US4716111A (en) 1982-08-11 1987-12-29 Trustees Of Boston University Process for producing human antibodies
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
EP1690934A3 (en) 1990-01-12 2008-07-30 Abgenix, Inc. Generation of xenogeneic antibodies
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
DE69233482T2 (de) 1991-05-17 2006-01-12 Merck & Co., Inc. Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
ATE390933T1 (de) 1995-04-27 2008-04-15 Amgen Fremont Inc Aus immunisierten xenomäusen stammende menschliche antikörper gegen il-8
CA2219486A1 (en) 1995-04-28 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5916771A (en) 1996-10-11 1999-06-29 Abgenix, Inc. Production of a multimeric protein by cell fusion method
EP0942968B1 (en) 1996-12-03 2008-02-27 Amgen Fremont Inc. Fully human antibodies that bind EGFR
CA2286879C (en) 1997-04-14 2003-12-16 Peter Kufer Novel method for the production of anti-human antigen receptors and uses thereof
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
US6613753B2 (en) 2001-02-21 2003-09-02 Supergen, Inc. Restore cancer-suppressing functions to neoplastic cells through DNA hypomethylation
DK1989546T3 (en) 2006-02-28 2016-11-21 Centre Léon Bérard SCREENING FOR ANTI-CANCER CONNECTIONS USING netrin-1 ACTIVITY
EP2050764A1 (en) 2007-10-15 2009-04-22 sanofi-aventis Novel polyvalent bispecific antibody format and uses thereof
NZ589719A (en) * 2008-06-09 2012-08-31 Cyclacel Ltd Combinations of sapacitabine or cndac with dna methyltransferase inhibitors such as decitabine and procaine
KR20140004632A (ko) 2010-08-26 2014-01-13 에프. 호프만-라 로슈 아게 DCC의 제 5 피브로넥틴 유형 III 도메인의 재조합 Fc-융합 단백질
EP2708231A1 (en) 2012-09-12 2014-03-19 Netris Pharma Combined treatment with netrin-1 interfering drug and chemotherapeutic drug
EP2893939A1 (en) 2014-01-10 2015-07-15 Netris Pharma Anti-netrin-1 antibody

Also Published As

Publication number Publication date
TW201720459A (zh) 2017-06-16
WO2017076864A1 (en) 2017-05-11

Similar Documents

Publication Publication Date Title
BR212016030926U2 (pt) conjugados de alvo e partículas e formulações dos mesmos
CL2023000848A1 (es) Terapia de combinación que incluye inhibidor de krasg12c y agente farmacéuticamente activo para tratar cáncer
BR112017018318A2 (pt) composição farmacêutica para tratar câncer compreendendo microrna como ingrediente ativo
BR112018003316A2 (pt) compostos e métodos para entrega transmembrana de moléculas
BR112018003985A2 (pt) macrociclos peptidomiméticos e usos dos mesmos
MX2021013830A (es) Inhibidores de ezh2 para tratar linfomas.
BR112019021822A2 (pt) Terapia de combinação
BR112017013597A2 (pt) molécula de ácido nucleico, composição farmacêutica, vetor ou célula, e, método para tratamento de uma doença.
NZ730296A (en) Modified double-stranded rna agents
WO2015106128A3 (en) Rnai agents modified at the 4'-c-position
BR112019004322A2 (pt) moduladores de receptor glicocorticoide para tratar câncer pancreático
EA201790674A1 (ru) Индуцирующий цитотоксичность терапевтический агент
BR112016022553A2 (pt) Compostos e métodos para entrega transmembrana de moléculas?
BR112013026494A2 (pt) composto, composição farmacêutica, método para tratar condição
CL2013003105A1 (es) Compuestos de microarn que comprende secuencias de nucleósidos modificados, inhibidores de mir-21; usos de los compuestos para modular la actividad de mir -21 y para preparar un medicamento para tratar fibrosis, heridas o cancer
BR112013005872A2 (pt) compostos, composição farmacêutica e respectivos usos
PE20150722A1 (es) Moduladores de la expresion de receptores androgenicos que comprenden un oligonucleotido modificado
BR112017025698A2 (pt) composições e métodos para inibir a expressão do gene de hif2alfa
BR112012029975A2 (pt) peptídeo como medicamento, em particular para o tratamento do câncer.
BR112017027985A2 (pt) peptídeos terapêuticos e métodos de uso dos mesmos
BR112018001292A2 (pt) métodos para melhor liberação de agentes ativos a tumores
PE20190381A1 (es) Oligonucleotidos antisentido para modular la expresion de htra1
AR081209A1 (es) Tratamiento de enfermedades relacionadas con la proteina 11 del tipo linfoma 2 de celulas b, (bcl2, bcl2l11) mediante la inhibicion del transcripto antisentido natural a bcl2l11
BR112015025025A2 (pt) composições terapêuticas e usos das mesmas
BR112018001435A2 (pt) métodos para entrega linfática de agentes ativos

Legal Events

Date Code Title Description
FB Suspension of granting procedure